RxDoctor Payments Data

Lauren Wright, PA

Physician Assistant · Raleigh, NCNPI 1891934410

Payments from drug & device makers

$9,718in general payments, 2019–2025

Across 568 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$703
  • Otsuka America Pharmaceutical, Inc.$678
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$556
  • Johnson & Johnson$445
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$9,60099%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,718 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$5,046
Medicare patients
28
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine18$146,146
RexultiBrexpiprazole29$51,789
CaplytaLumateperone Tosylate13$21,466
Aripiprazole21$1,388
Naltrexone Hcl18$1,331
Trazodone Hcl46$959
Quetiapine Fumarate39$955
Olanzapine33$916
Lamotrigine64$888
AmantadineAmantadine Hcl24$745
Duloxetine Hcl26$665
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$439
Lurasidone Hcl13$410
Bupropion XlBupropion Hcl24$367
Divalproex Sodium ErDivalproex Sodium12$367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$703$146,14618 claims
Otsuka America Pharmaceutical, Inc.Rexulti$678$51,78929 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$556$21,46613 claims
Almatica Pharma LLCSertraline Hcl$265$16514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →